A recent randomized controlled trial demonstrated the bioequivalence between universally applicable and AB0 compatible transfusion plasma in healthy volunteers. There was a limited change in coagulation factor levels and inhibitors before and after plasmapheresis and subsequent plasma transfusion. The aim of this extension trial was to investigate the true capacity of these plasma products to restore baseline levels of coagulation factors and inhibitors after plasma depletion in comparison to haemodilution induced by infusion of albumin solution.Fourteen healthy subjects, who completed both plasma transfusion periods, underwent an additional plasmapheresis (600 mL) followed by an infusion of 1200 mL albumin (3.125

作者：Petra, Jilma-Stohlawetz；Friedrich W, Kursten；Michaela, Horvath；Gerda, Leitner；Jana, List；Jana, Marcek；Peter, Quehenberger；Michael, Schwameis；Johann, Bartko；Bernd, Jilma

来源：Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2015 年 53卷 3期